https://www.live-feeds.com/feed/amgen-drug-combined-with-immunotherapy-extends-survival-in-lung-cancer-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/amgen-drug-combined-with-immunotherapy-extends-survival-in-lung-cancer-trialhttps://www.live-feeds.com/feed/amgen-drug-combined-with-immunotherapy-extends-survival-in-lung-cancer-trial#u160844Thu, 29 Oct 2026 05:01:18 +0000Amgen's Imdelltra combined with AstraZeneca's immunotherapy Imfinzi reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer. The phase 3 trial, DeLLphi-305, showed that the combination extended median overall survival to 21.1 months compared to 12.7 months with Imfinzi alone. Nearly 80% of patients were alive at one year versus 53% with Imfinzi alone.Why it mattersSmall cell lung cancer is an aggressive and hard-to-treat disease. Current treatments have limited efficacy, making new therapies crucial. The combination of Imdelltra and Imfinzi offers a s